BioSpectrum Asia Magazine - July 2020Add to Favorites

BioSpectrum Asia Magazine - July 2020Add to Favorites

Go Unlimited with Magzter GOLD

Read BioSpectrum Asia along with 8,500+ other magazines & newspapers with just one subscription  View catalog

1 Month $9.99

1 Year$99.99 $49.99

$4/month

Save 50% Hurry, Offer Ends in 5 Days
(OR)

Subscribe only to BioSpectrum Asia

1 Year $10.99

Save 7%

Buy this issue $0.99

Gift BioSpectrum Asia

7-Day No Questions Asked Refund7-Day No Questions
Asked Refund Policy

 ⓘ

Digital Subscription.Instant Access.

Digital Subscription
Instant Access

Verified Secure Payment

Verified Secure
Payment

In this issue

Firms racing to develop antibody treatment for COVID-19

The Coronavirus COVID-19 has raged the world and has infected 8,993,659 cases and killed 469,587 (as of June 23, 2020. Source World Health Organization (WHO)). Pharma firms, scientists and governments all over the world are racing to find a cure for the virus. The entire world is waiting for the vaccine; Moderna’s mRNA vaccine will begin phase III study in July. Amidst all this, some biopharma companies are pushing to develop antibody based treatments for the virus. Does that have any merit? Why are firms putting billions of dollars into it when vaccines are the ultimate solution? Let’s find out.

Daiichi Sankyo enters research collaboration for COVID-19

The University of Tokyo, RIKEN, Nichi-Iko Pharmaceutical and Daiichi Sankyo in Japan have reached a basic agreement on collaborative R&D on a Nafamostat inhalation formulation for the treatment of novel coronavirus infection.

Daiichi Sankyo enters research collaboration for COVID-19

1 min

Firms Racing To Develop Antibody Treatment For Covid-19

The Coronavirus COVID-19 has raged the world and has infected 8,993,659 cases and killed 469,587 (as of June 23, 2020. Source World Health Organization (WHO)). Pharma firms, scientists and governments all over the world are racing to find a cure for the virus. The entire world is waiting for the vaccine; Moderna’s mRNA vaccine will begin phase III study in July. Amidst all this, some biopharma companies are pushing to develop antibody-based treatments for the virus. Does that have any merit? Why are firms putting billions of dollars into it when vaccines are the ultimate solution? Let’s find out.

Firms Racing To Develop Antibody Treatment For Covid-19

10+ mins

Controversial papers in NEJM and The Lancet - A KNEE-JERKER DURING PANDEMIC?

Praised as a potential miracle cure, hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease. But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective, but are downright deadly.

Controversial papers in NEJM and The Lancet - A KNEE-JERKER DURING PANDEMIC?

10 mins

So Far Covid-19 Has Limited Impact On Our Business

Established by Dr Samantha Du in 2014, China-based Zai Lab, a biopharmaceutical company, has an impressive track record.

So Far Covid-19 Has Limited Impact On Our Business

4 mins

“Investment will flow towards digital solutions to augment treatment”

In 2017, Dr Ruchir Mehra, Harsh V Bansal, and Richeek Arya, came together and started Remedo as a digital engagement platform to help doctors effectively manage their patients with chronic diseases, providing end-to-end care in their recovery process.

“Investment will flow towards digital solutions to augment treatment”

4 mins

“We see already a higher awareness of why life science needs to be a priority for Japan and Australia”

Cytiva (formerly part of GE Healthcare Life Sciences), a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics, has joined hands with Takara Bio to manufacture a DNA vaccine candidate for COVID-19.

“We see already a higher awareness of why life science needs to be a priority for Japan and Australia”

4 mins

Read all stories from BioSpectrum Asia

BioSpectrum Asia Magazine Description:

PublisherMM Activ Sci-Tech Communication

CategoryBusiness

LanguageEnglish

FrequencyMonthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

  • cancel anytimeCancel Anytime [ No Commitments ]
  • digital onlyDigital Only
MAGZTER IN THE PRESS:View All